Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial

BACKGROUND: In acute myeloid leukaemia (AML), interleukin-6 (IL-6) promotes chemo-resistance and its levels correlate with poor prognosis. IL-6 blockade may represent a promising therapeutic strategy. We aimed to test, tocilizumab, an anti-IL-6 receptor (R) monoclonal antibody in combination with st...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterlin, Pierre, Garnier, Alice, Le Bourgeois, Amandine, Guillaume, Thierry, Le Bris, Yannick, Theisen, Olivier, Béné, Marie C., Eveillard, Marion, Rimbert, Marie, Jullien, Maxime, Planche, Lucie, Gaschet, Joelle, Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542006/
https://www.ncbi.nlm.nih.gov/pubmed/37786451
http://dx.doi.org/10.1016/j.eclinm.2023.102254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542006/
https://www.ncbi.nlm.nih.gov/pubmed/37786451
http://dx.doi.org/10.1016/j.eclinm.2023.102254

Ejemplares similares